Pharmaceuticals, Biotechnology and Life Sciences
Roche’s new tablet for treating certain types of idiopathic pulmonary fibrosis (IPF) was approved by the European Commission, the Swiss drugmaker announced on Tuesday.
Jury selection in the New York trial of former drug company executive Martin Shkreli will enter its third day Wednesday, after some potential jurors said they could not be fair to a man who gained notoriety by raising the price of a life-saving drug more than 5,000 percent.
Novartis ahs won European clerance for Erelzi, as the European Commission approved it for Novartis’s division Sandoz.
A recent survey on the state of label management in the pharmaceutical industry undertaken by NiceLabel in cooperation with Pharmaceutical Manufacturing reveals the challenges facing pharmaceutical manufacturers as they try to produce accurate, compliant labels, and highlights the increasing importance of a single, integrated label management system.
An exclusive License and Supply Agreement (LSA) has been signed between Fuji Pharma, the leader in women’s health in Japan, and Mithra, a Euronext -listed company specialized in women’s health, for the commercialization of Donesta in Japan and ASEAN territories.
CSL Behring LLC, has gotten the FDA’s approval of Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.
Novo Nordisk got the right from the European Medicines Agency’s committee (EMA) to include data from the LEADER trial to Saxenda to the results from the trial showed the long-term effects of Victoza for type 2 diabetes and established cardiovascular disease patients.
Novartis was cleared on Thursday by the US Food and Drug Administration (FDA) for combination of Tafinlar (dabrafenib) with Mekinist (trametinib) for treating metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express the BRAF V600E mutation, which is fourth actionable genomic biomaker in metastatic NSCLC
Novartis’s Phase III Cantos study of ACZ885 (canakinumab), one of the largest in the company’s history, combined with standard of care in people with a prior heart attack and inflammatory atherosclerosis has met the primary endpoint.
ValiRx’s has formed an Advisory Board to support its main board in new strategic guidance and technical advice.